Medeus Deals Quickly for Skye's Depomorphine

Newly-created Medeus Pharma hasn't waited long to sign its first in-licensing deal. Only two months after its creation, through the acquisition of Elan's European sales and marketing infrastructure, the firm has secured European rights to SkyePharma's sustained-release post-op pain treatment DepoMorphine for €100 million. SkyePharma continues shifting the source of its revenues from milestone payments to more predictable royalties; Medeus flexes its muscle as a viable, fast-moving competitor to larger pan-European in-licensers.

Medeus Pharma Ltd. CEO Bryan Morton likes to plan ahead. Although Morton didn't close the Apax Partners-backed deal to acquire Elan Corp. PLC 's European sales and marketing infrastructure for $120 million until mid-February 2004 [See Deal], creating Medeus, Morton and chief business officer Felix Botelho had set their sights on the European rights to SkyePharma PLC 's sustained-release morphine product DepoMorphine six months earlier, in September 2003. Medeus, which aims to leverage its continent-wide commercial network into status as a European partner of choice, has spent months identifying such opportunities. (See "Medeus: How to Find & Buy a Ready-Made Euro Infrastructure," In Vivo Europe Rx, April 2004 Also see "Medeus: How To Find & Buy a Ready-Made Euro Infrastructure " - In Vivo, 1 April, 2004..)

SkyePharma was anxious to sign a partner in Europe for DepoMorphine, for which it expects UK approval by the end...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Deal-Making

More from In Vivo